WingerchukDMBanwellBBennettJL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology2015; 85: 177–189.
2.
SiriratnamPHudaSButzkuevenH, et al. A comprehensive review of the advances in neuromyelitis optica spectrum disorder. Autoimmun Rev2023; 22(12): 103465.
3.
PalaceJLinDYZengD, et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain2019; 142: 1310–1323.
4.
KrettJDFilippatouAGBarrerasP, et al. ‘Lupus myelitis’ revisited: A retrospective single-center study of myelitis associated with rheumatologic disease. Neurol Neuroimmunol Neuroinflamm2025; 12(1): e200329.
5.
EspositoJEAnnoniGD’AmatoM, et al. Systemic connective tissue disease and neuromyelitis optica spectrum disorder coexistence: A systematic review and meta-analysis. J Integr Neurosci2024; 23: 35.
6.
AlexopoulosHKampylafkaEIFoukaP, et al. Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease. J Neuroimmunol2015; 289: 8–11.
7.
WatersPJMcKeonALeiteMI, et al. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays. Neurology2012; 78: 665–671.
8.
MajedMValencia SanchezCBennettJL, et al. Alterations in aquaporin-4-IgG Serostatus in 986 Patients: A laboratory-based longitudinal analysis. Ann Neurol2023; 94(4): 727–735.
9.
McGlassonSWisemanSWardlawJ, et al. Neurological disease in lupus: Toward a personalized medicine approach. Front Immunol2018; 9: 1146.
10.
FrancisAGibbonsEYuJ, et al. Characterizing mortality in patients with AQP4-Ab+ neuromyelitis optica spectrum disorder. Ann Clin Transl Neurol2024; 11(7): 1942–1947.
